News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
712,512 Results
Type
Article (56497)
Company Profile (305)
Press Release (655693)
Multimedia
Podcasts (160)
Webinars (22)
Section
Business (196584)
Career Advice (2849)
Deals (35635)
Drug Delivery (140)
Drug Development (83522)
Employer Resources (172)
FDA (17235)
Job Trends (16013)
News (343367)
Policy (34811)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2886)
Accelerated approval (34)
Adcomms (36)
Allergies (147)
Alliances (49913)
ALS (177)
Alzheimer's disease (1746)
Antibody-drug conjugate (ADC) (340)
Approvals (17424)
Artificial intelligence (564)
Autoimmune disease (167)
Automation (38)
Bankruptcy (360)
Best Places to Work (11918)
BIOSECURE Act (22)
Biosimilars (204)
Biotechnology (171)
Bladder cancer (163)
Brain cancer (64)
Breast cancer (662)
Cancer (4967)
Cardiovascular disease (444)
Career advice (2422)
Career pathing (41)
CAR-T (302)
CDC (56)
Celiac Disease (2)
Cell therapy (796)
Cervical cancer (36)
Clinical research (71243)
Collaboration (1804)
Company closure (5)
Compensation (701)
Complete response letters (72)
COVID-19 (2957)
CRISPR (97)
C-suite (872)
Cystic fibrosis (149)
Data (6255)
Decentralized trials (2)
Denatured (46)
Depression (147)
Diabetes (530)
Diagnostics (6820)
Digital health (42)
Diversity (11)
Diversity, equity & inclusion (41)
Drug discovery (258)
Drug pricing (222)
Drug shortages (35)
Duchenne muscular dystrophy (240)
Earnings (79289)
Editorial (65)
Employer branding (22)
Employer resources (155)
Events (104682)
Executive appointments (1016)
FDA (20400)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (1514)
Gene editing (209)
Generative AI (51)
Gene therapy (652)
GLP-1 (1119)
Government (5096)
Grass and pollen (8)
Guidances (386)
Healthcare (19197)
HIV (62)
Huntington's disease (48)
IgA nephropathy (86)
Immunology and inflammation (283)
Immuno-oncology (60)
Indications (103)
Infectious disease (3244)
Inflammatory bowel disease (194)
Inflation Reduction Act (15)
Influenza (117)
Intellectual property (246)
Interviews (527)
IPO (15896)
IRA (57)
Job creations (4425)
Job search strategy (2000)
JPM (68)
Kidney cancer (16)
Labor market (79)
Layoffs (644)
Leadership (40)
Legal (8231)
Liver cancer (98)
Longevity (15)
Lung cancer (677)
Lymphoma (379)
Machine learning (42)
Management (61)
Manufacturing (824)
MASH (171)
Medical device (13773)
Medtech (13821)
Mergers & acquisitions (20770)
Metabolic disorders (1396)
Multiple sclerosis (170)
NASH (23)
Neurodegenerative disease (350)
Neuropsychiatric disorders (99)
Neuroscience (3060)
Neurotech (1)
NextGen: Class of 2026 (6959)
Non-profit (4910)
Now hiring (62)
Obesity (683)
Opinion (323)
Ovarian cancer (166)
Pain (216)
Pancreatic cancer (228)
Parkinson's disease (297)
Partnered (34)
Patents (490)
Patient recruitment (493)
Peanut (59)
People (59792)
Pharmaceutical (92)
Pharmacy benefit managers (33)
Phase 1 (22126)
Phase 2 (31125)
Phase 3 (23649)
Pipeline (5216)
Policy (332)
Postmarket research (2761)
Preclinical (9015)
Press Release (65)
Prostate cancer (246)
Psychedelics (55)
Radiopharmaceuticals (278)
Rare diseases (905)
Real estate (6265)
Recruiting (74)
Regulatory (26112)
Reports (40)
Research institute (2611)
Resumes & cover letters (434)
Rett syndrome (28)
RNA editing (16)
RSV (85)
Schizophrenia (158)
Series A (255)
Series B (195)
Service/supplier (13)
Sickle cell disease (103)
Special edition (25)
Spinal muscular atrophy (170)
Sponsored (40)
Startups (3806)
State (2)
Stomach cancer (19)
Supply chain (111)
Tariffs (101)
The Weekly (112)
Vaccines (1129)
Venture capital (97)
Weight loss (470)
Women's health (85)
Worklife (22)
Date
Today (87)
Last 7 days (541)
Last 30 days (2040)
Last 365 days (29723)
2026 (2928)
2025 (30080)
2024 (34627)
2023 (39505)
2022 (50359)
2021 (54986)
2020 (54381)
2019 (48034)
2018 (36864)
2017 (33924)
2016 (33467)
2015 (38107)
2014 (30416)
2013 (25508)
2012 (27393)
2011 (28022)
2010 (25515)
Location
Africa (995)
Alabama (86)
Alaska (7)
Arizona (256)
Arkansas (14)
Asia (43558)
Australia (7162)
California (10913)
Canada (3081)
China (1124)
Colorado (471)
Connecticut (450)
Delaware (301)
Europe (97526)
Florida (1556)
Georgia (330)
Hawaii (4)
Idaho (62)
Illinois (869)
India (65)
Indiana (522)
Iowa (21)
Japan (428)
Kansas (126)
Kentucky (42)
Louisiana (25)
Maine (80)
Maryland (1324)
Massachusetts (7358)
Michigan (312)
Minnesota (631)
Mississippi (6)
Missouri (134)
Montana (29)
Nebraska (28)
Nevada (118)
New Hampshire (84)
New Jersey (2860)
New Mexico (32)
New York (2867)
North Carolina (1478)
North Dakota (10)
Northern California (5209)
Ohio (310)
Oklahoma (21)
Oregon (46)
Pennsylvania (2106)
Puerto Rico (23)
Rhode Island (47)
South America (1349)
South Carolina (63)
South Dakota (1)
Southern California (4332)
Tennessee (173)
Texas (1634)
United States (38134)
Utah (348)
Vermont (1)
Virginia (278)
Washington D.C. (85)
Washington State (895)
West Virginia (4)
Wisconsin (114)
Wyoming (2)
712,512 Results for "maat pharma sa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival
December 9, 2025
·
7 min read
Press Releases
MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034
November 5, 2025
·
6 min read
Press Releases
MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis
January 21, 2026
·
6 min read
Press Releases
MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
October 7, 2025
·
4 min read
Press Releases
MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update
November 4, 2025
·
6 min read
Press Releases
MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease Selected for Oral Presentation at ASH Congress 2025
November 3, 2025
·
7 min read
Press Releases
MaaT Pharma Publishes Its Half Year 2025 Results and Provides a Business Update
September 17, 2025
·
15 min read
Press Releases
MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting
June 25, 2025
·
4 min read
Press Releases
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025
June 19, 2025
·
8 min read
Press Releases
MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress
May 15, 2025
·
4 min read
1 of 71,252
Next
